Research Highlights
The research in the Kohn lab focuses on the development of new methods to treated genetic diseases of blood cells by gene modification of hematopoietic stem cells. Dr. Kohn’s group was the first (and still the only one) to perform a clinical trial with gene transfer to umbilical cord blood CD34+ cells for a genetic disorder (ADA-SCID in 1993) and the first in the U.S. to initiate clinical trials of gene therapy for pediatric HIV/AIDS using bone marrow stem cells. Current projects include:
- Performing clinical trials for ADA-deficient SCID, XSCID, Sickle Cell Disease and X-linked Chronic Granulomatous Disease
- Developing new lentiviral vectors for regulated gene expression,
- Advancing techniques for site-specific gene editing for sickle cell disease and primary immune deficiency diseases
- Improving clinical hematopoietic stem cell processing.
Our research group spans the bench-to-bedside spectrum and provides an excellent training environment for physician/scientists.
Featured Publications
Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing. McAuley GE, Yiu G, Chang PC, Newby GA, Campo-Fernandez B, Fitz-Gibbon ST, Wu X, Kang SL, Garibay A, Butler J, Christian V, Wong RL, Everette KA, Azzun A, Gelfer H, Seet CS, Narendran A, Murguia-Favela L, Romero Z, Wright N, Liu DR, Crooks GM, Kohn DB. Cell. 2023. 186:1398-1416.e23. PMID: 36944331
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease Recapitulates Endogenous CYBB Regulation and Expression. Wong RL, Sackey S, Brown D, Senadheera S, Masiuk K, Quintos JP, Colindres N, Riggan L, Morgan RA, Malech HL, Hollis RP, Kohn DB. Blood. 2022 Nov 4:blood. Online ahead of print. PMID: 36332160
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, Carbonaro-Sarracino DA, Soni K, Terrazas D, Snell K, Ikeda A, Leon-Rico D, Moore TB, Buckland KF, Shah AJ, Gilmour KC, De Oliveira S, Rivat C, Crooks GM, Izotova N, Tse J, Adams S, Shupien S, Ricketts H, Davila A, Uzowuru C, Icreverzi A, Barman P, Campo Fernandez B, Hollis RP, Coronel M, Yu A, Chun KM, Casas CE, Zhang R, Arduini S, Lynn F, Kudari M, Spezzi A, Zahn M, Heimke R, Labik I, Parrott R, Buckley RH, Reeves L, Cornetta K, Sokolic R, Hershfield M, Schmidt M, Candotti F, Malech HL, Thrasher AJ, Gaspar HB. N Engl J Med. 2021 May 27;384(21):2002-2013. PMID: 33974366
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Reinhardt B, Habib O, Shaw KL, Garabedian E, Carbonaro-Sarracino DA, Terrazas D, Fernandez BC, De Oliveira S, Moore TB, Ikeda AK, Engel BC, Podsakoff GM, Hollis RP, Fernandes A, Jackson C, Shupien S, Mishra S, Davila A, Mottahedeh J, Vitomirov A, Meng W, Rosenfeld AM, Roche AM, Hokama P, Reddy S, Everett J, Wang X, Luning Prak ET, Cornetta K, Hershfield MS, Sokolic R, De Ravin SS, Malech HL, Bushman FD, Candotti F, Kohn DB. Blood. 2021 Oct 14;138(15):1304-1316. PMID: 33974038
Lentiviral gene therapy for X-linked chronic granulomatous disease. Kohn DB, Booth C, Kang EM, Pai SY, Shaw KL, Santilli G, Armant M, Buckland KF, Choi U, De Ravin SS, Dorsey MJ, Kuo CY, Leon-Rico D, Rivat C, Izotova N, Gilmour K, Snell K, Dip JX, Darwish J, Morris EC, Terrazas D, Wang LD, Bauser CA, Paprotka T, Kuhns DB, Gregg J, Raymond HE, Everett JK, Honnet G, Biasco L, Newburger PE, Bushman FD, Grez M, Gaspar HB, Williams DA, Malech HL, Galy A, Thrasher AJ; Net4CGD consortium. Nat Med. 2020 Feb;26(2):200-206. PMID: 31988463
Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. Romero Z, Lomova A, Said S, Miggelbrink A, Kuo CY, Campo-Fernandez B, Hoban MD, Masiuk KE, Clark DN, Long J, Sanchez JM, Velez M, Miyahira E, Zhang R, Brown D, Wang X, Kurmangaliyev YZ, Hollis RP, Kohn DB. Mol Ther. 2019 Aug 7;27(8):1389-1406. PMID: 31178391
Featured News
What a decade of gene therapy research for sickle cell disease taught UCLA scientists
When Dr. Donald Kohn began performing bone marrow transplants in 1987, he saw firsthand the promise and limitations of available...
“Night and day”: Adventuring through childhood with newfound immune systems
Seven years ago, Jon and Alicia Langenhop learned that all three of their children suffered from the same devastating, one-in-a-million...
FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder
Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. This week, his...
Exposure to any germs could’ve killed her. 11 years later, she’s living a normal life thanks to a gene therapy treatment.
Two months after she was born, Eliana Nachem got a cough that wouldn’t go away. Three weeks later, she also...
Scientists are inventing treatments for devastating diseases. There’s just one problem.
This past spring, a biotech company announced the first use of a new gene-editing technology in people to fix an...
Gene therapy delivers lasting immune protection in children with rare disorder
An experimental gene therapy developed by researchers at UCLA, University College London and Great Ormond Street Hospital has restored and...






